Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
HighTide TherapeuticsHTTIF 14 Operating Cash Flow per Share is $-0.05 as of Dec. 2025. GuruFocus rates HTTIF with a GF Score™ of 14/100. The stock has 3 warning signs investors should review. Among 1,138 Biotechnology companies, HighTide Therapeutics ranks better than 53.34% on this metric.
HighTide Therapeutics's operating cash flow per share for the
six
months ended in Dec. 2025 was $-0.01.
HighTide Therapeutics's operating cash flow per share for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.05.
During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 20.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.
The historical rank and industry rank for HighTide Therapeutics's Operating Cash Flow per Share or its related term are showing as below:
HTTIF'
s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: -48.6 Med: -14.2 Max: 20.2
Current: 20.2
During the past 5 years, HighTide Therapeutics's highest 3-Year average Operating Cash Flow per Share Growth Rate was 20.20% per year. The lowest was -48.60% per year. And the median was -14.20% per year.
HTTIF's 3-Year OCF Growth Rate is ranked better than 53.34% of 1138
companies
in the Biotechnology industry
Industry Median: 17
vs HTTIF: 20.20
HighTide Therapeutics Operating Cash Flow per Share Related Terms
HighTide Therapeutics Operating Cash Flow per Share Historical Data
* Premium members only.
The historical data trend for HighTide Therapeutics's Operating Cash Flow per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HighTide Therapeutics Operating Cash Flow per Share Chart
HTTIF vs VRTX, REGN, RVMD: Operating Cash Flow per Share Comparison
For the Biotechnology subindustry, HighTide Therapeutics's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
HighTide Therapeutics Price-to-Operating-Cash-Flow vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, HighTide Therapeutics's Price-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where HighTide Therapeutics's Price-to-Operating-Cash-Flow falls into.
Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-0.05
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Operating Cash Flow per Share of $-0.05 mean?
HighTide Therapeutics (HTTIF) has a Operating Cash Flow per Share of $-0.05 as of Dec. 2025. Operating cash flow per share equals the per-share amount of cash flow from operations. View historical data on HighTide Therapeutics and its competitors. According to the industry distribution chart, HighTide Therapeutics ranks #531 out of 1138 companies in the Biotechnology industry, placing it in the top 46.7%.
Is HighTide Therapeutics' Operating Cash Flow per Share too high?
HighTide Therapeutics' current Operating Cash Flow per Share is $-0.05. Based on the distribution chart, HighTide Therapeutics ranks #531 out of 1138 companies in the Biotechnology industry, which is above the industry midpoint. Overall, HighTide Therapeutics has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does HighTide Therapeutics' Operating Cash Flow per Share compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, HighTide Therapeutics ranks #531 out of 1138 companies for Operating Cash Flow per Share. This puts HighTide Therapeutics in the upper half of its industry. The industry median Operating Cash Flow per Share is 17.00. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Cash Flow per Share for a Biotechnology company?
The median Operating Cash Flow per Share among Biotechnology companies is 17.00, based on 1,138 companies in the industry. Companies in the top quartile (top 25%) have a Operating Cash Flow per Share significantly above this median, while those in the bottom quartile fall well below. However, Operating Cash Flow per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Cash Flow per Share mean?
A high Operating Cash Flow per Share can signal that a stock is expensive relative to its fundamentals. Operating cash flow per share equals the per-share amount of cash flow from operations. View historical data on HighTide Therapeutics and its competitors. For the Biotechnology industry, the median Operating Cash Flow per Share is 17.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. HighTide Therapeutics's current Operating Cash Flow per Share is $-0.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HighTide Therapeutics stock overvalued right now?
HighTide Therapeutics (HTTIF) has a current Operating Cash Flow per Share of $-0.05. The current Operating Cash Flow per Share is $-0.05. HighTide Therapeutics' overall GF Score™ is 14/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Cash Flow per Share calculated?
Operating Cash Flow per Share is calculated from a company's financial statements. For HighTide Therapeutics (HTTIF), the current Operating Cash Flow per Share is $-0.05 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
HighTide Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of first-in-class multifunctional, multi-targeted therapies for cardiovascular-kidney-metabolic (CKM) diseases and related metabolic disorders. The company is developing a pipeline of proprietary drug candidates targeting indications including type 2 diabetes mellitus, chronic kidney disease, obesity, metabolic dysfunction-associated steatohepatitis (MASH), and primary sclerosing cholangitis (PSC). Its core product candidate, HTD1801 (berberine ursodeoxycholate), is an orally delivered first-in-class anti-inflammatory metabolic modulator designed to target dual pathways involving AMPK activation and NLRP3 inflammasome inhibition.
14GF Score
Get the complete analysis for HTTIF
Operating Cash Flow per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HTTIF has been successfully added to your 
